Welcome to Arctom, sign up to enjoy up to 20% OFF
- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 2353-33-5] Decitabine
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-A0004 |
| Brand: | MCE |
| CAS: | 2353-33-5 |
Overview
| MDL | MFCD00043011 |
|---|---|
| Molecular Weight | 228.21 |
| Molecular Formula | C8H12N4O4 |
| SMILES | O[C@H]1C[C@H](N2C(N=C(N)N=C2)=O)O[C@@H]1CO |
For research use only. We do not sell to patients.
62 Publications Citing Use of MCE
- [1]Ann Rheum Dis. 2019 Oct;78(10):1420-1429.
- [2]Nat Commun. 2023 Jan 10;14(1):18.
- [3]Neuro Oncol. 2022 Jun 21;noac157.
- [4]J Allergy Clin Immunol. 2019 Jun;143(6):2038-2051.e12.
- [5]Prog Neurobiol. 2021 Feb 23;102028.
- [6]Theranostics. 2021 Mar 20;11(11):5605-5619.
- [7]Theranostics. 2020 Sep 15;10(25):11444-11461.
- [8]Cell Rep. 2022 Oct 25;41(4):111561.
- [9]Oncogene. 2021 Apr;40(15):2711-2724.
- [10]Oncogene. 2020 Aug;39(33):5507-5519.
- [11]Cancer Lett. 2022 Sep 8;215904.
- [12]Clin Chem. 2019 Dec;65(12):1522-1531.
- [13]J Invest Dermatol. 2020 Dec;140(12):2442-2454.e5.
- [14]Mol Oncol. 2021 May;15(5):1566-1583.
- [15]Cell Death Dis. 2023 Jan 25;14(1):59.
- [16]Cell Death Dis. 2022 Dec 24;13(12):1070.
- [17]Cell Death Dis. 2021 Jun 23;12(7):642.
- [18]Cell Death Dis. 2019 Feb 20;10(3):169.
- [19]Cancers (Basel). 2022, 14(23), 5854
- [20]Cancers (Basel). 2020 Oct 16;12(10):3009.
- [21]Cancers. 2019 Dec 9;11(12):1984.
- [22]Pharmacol Res. 2022 Jun;180:106244.
- [23]Int J Radiat Oncol Biol Phys. 2022 Jul 30;S0360-3016(22)02596-2.
- [24]Cell Prolif. 2021 May 24;e13072.
- [25]Rheumatology. 2022 Aug 3;61(8):3471-3480.
- [26]Front Cell Dev Biol. 2021 Mar 15;9:647527.
- [27]Int J Cancer. 2021 Apr 1;148(7):1743-1755.
- [28]Oxid Med Cell Longev. 2022 Mar 29;2022:2371807.
- [29]Acta Pharmacol Sin. 2021 Apr 13.
- [30]Bioorg Chem. 2022 Jul;124:105800.
- [31]Int J Mol Sci. 2022 Aug 22;23(16):9481.
- [32]Int J Mol Sci. 2022 Feb 14;23(4):2117.
- [33]Nutrients. 2022, 14(12), 2508.
- [34]Biomed Pharmacother. 2022 Jan 25;147:112662.
- [35]J Cell Mol Med. 2021 May 7.
- [36]Nanomedicine. 2022 Nov 18;102627.
- [37]Sci Rep. 2020 Sep 16;10(1):15201.
- [38]Sci Rep. 2019 Jun 3;9(1):8171.
- [39]Int Immunopharmacol. 2021, 107820.
- [40]Viruses. 2022, 14(7), 1485.
- [41]Int J Biochem Cell Biol. 2021 Nov 18;106117.
- [42]J Cancer. 2021 Jan 1;12(3):874-884.
- [43]Exp Cell Res. 2020 Aug 1;393(1):112054.
- [44]Onco Targets Ther. 2018 Sep 10;11:5631-5646.
- [45]Aquaculture. 2023: 739234.
- [46]BMC Cancer. 2023 Jan 25;23(1):87.
- [47]RSC Adv. 2021, 11, 38907-38914.
- [48]Gene. 2022 Jun 21;146689.
- [49]Thorac Cancer. 2019 Jun;10(6):1388-1394.
- [50]Cell Biol Int. 2022 Jul 16.
- [51]Cell Biol Int. 2020 Feb;44(2):603-609.
- [52]J Oncol. 2022 Jun 23;2022:8724933.
- [53]Exp Ther Med. July 5, 2022.
- [54]Genes Genomics. 2022 May 14.
- [55]Research Square Print. September 20th, 2022.
- [56]bioRxiv. February 15, 2022.
- [57]Research Square Preprint. 2021 May.
- [58]Stem Cell Rev Rep. 2021 Jun;17(3):938-951.
- [59]Research Square Preprint. 2020 Jul.
- [60]der Fakultät für Biologie an der, Universität Duisburg-Essen. 2019 Aug.
- [61]Patent. US20180263995A1.
- [62]Harvard Medical School LINCS LIBRARY
Summary
Decitabine (NSC 127716) is an orally active deoxycytidine analogue antimetabolite and a DNA methyltransferase inhibitor. Decitabine incorporates into DNA in place of cytosine can covalently trap DNA methyltransferase to DNA causing irreversible inhibition of the enzyme. Decitabine induces cell G2/M arrest and cell apoptosis . Decitabine has potent anticancer activity [1] [2] .
IC50 & Target
|
DNMT1
|
DNMT3A
|
DNMT3B
|
In Vitro
Decitabine treatment significantly inhibits cell growth of SNU719, NCC24 and KATOIII 96 hours after exposure to decitabine. Decitabine induces G2/M arrest and apoptosis in EBVaGC, inhibits invasion ability, and up-regulates E-cadherin expression for EBVaGC
[1]
.
Only high concentrations (10 µM) Decitabine (0.1-1 μM; 24-72 hours) results in a G2 phase arrest, which is accompanied by a reduction of cells in G1 phase
[3]
.
Decitabine up-regulates DCTPP1 and dUTPase expression in HeLa cells
[4]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Cycle Analysis [1]
| Cell Line: | HCT116 cells |
| Concentration: | 0.1, 1, 10 µM |
| Incubation Time: | 24, 48, 72 hours |
| Result: | Only high drug concentrations (10 µM) resulted in a G2 phase arrest, which was accompanied by a reduction of cells in G1 phase. |
In Vivo
Decitabine (1.0 mg/kg, p.o.) in combination with tetrahydrouridine (THU) causes severe toxicity occurs in female CD-1 mice, and results in an increased sensitivity to decitabine toxicity correlating with decitabine plasma levels
[5]
.
Decitabine (1.0 mg/kg; i.p.; once daily for 5 consecutive days) leads to regression of EL4 tumors established in C57BL/6 Mice
[7]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | C57BL/6 mice (bearing EL4 cells) [6] |
| Dosage: | 1.0 mg/kg |
| Administration: | Intraperitoneal injection; once daily for 5 consecutive days |
| Result: | Caused continuous tumor regression even after Decitabine treatment was stopped. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04283526 | Novartis Pharmaceuticals|Novartis |
Primary Myelofibrosis|Myelofibrosis|PMF|Post-Essential Thrombocythemia Myelofibrosis|Post-Polycythemia Vera Myelofibrosis
|
November 30, 2020 | Phase 1 |
| NCT01690507 | Chinese PLA General Hospital|Navy General Hospital, Beijing |
MDS|AML
|
November 2012 | Phase 1|Phase 2 |
| NCT03233724 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Carcinoma, Non-Small-Cell Lung|Lung Cancer|Non-Small Cell Lung Cancer|Carcinoma, Esophageal|Malignant Pleural Mesotheliomas
|
April 11, 2018 | Phase 1|Phase 2 |
| NCT00671697 | Washington University School of Medicine|Cephalon |
Myelodysplastic Syndromes and Leukemia, Myeloid, Acute
|
May 2008 | Phase 1 |
| NCT02316964 | Sumithira Vasu|Ohio State University Comprehensive Cancer Center |
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia
|
April 21, 2015 | Phase 1 |
| NCT03558412 | Mingzhi Zhang|Zhengzhou University |
T-lymphoblastic Lymphoma
|
June 1, 2018 | Phase 4 |
| NCT01098084 | Groupe Francophone des Myelodysplasies|Janssen-Cilag Ltd. |
Chronic Myelomonocytic Leukemia
|
November 2008 | Phase 2 |
| NCT01400633 | Janssen Korea, Ltd., Korea |
Myelodysplastic Syndromes
|
December 2010 | |
| NCT01673217 | Roswell Park Cancer Institute|Eisai Inc. |
Recurrent Fallopian Tube Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Primary Peritoneal Cavity Cancer
|
April 2009 | Phase 1 |
| NCT03377725 | Li Junmin|Ruijin Hospital |
Myelodysplastic Syndromes|P53 Mutation
|
March 2018 | Phase 3 |
| NCT03021395 | Institute of Hematology & Blood Diseases Hospital |
AML
|
February 8, 2017 | Phase 1|Phase 2 |
| NCT02472145 | Janssen Research & Development, LLC |
Leukemia, Myeloid, Acute
|
August 4, 2015 | Phase 2|Phase 3 |
| NCT03013998 | Beat AML, LLC |
Previously Untreated Acute Myeloid Leukemia
|
November 2016 | Phase 1|Phase 2 |
| NCT00041990 | Astex Pharmaceuticals, Inc.|Eisai Inc. |
Chronic Myelogenous Leukemia
|
July 2002 | Phase 2 |
| NCT01375608 | National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) |
Neutropenia|Sickle Cell Disease
|
June 2011 | Phase 2 |
| NCT00479232 | Merck Sharp & Dohme LLC |
Leukemia, Myelocytic, Acute Myelodysplastic Syndromes|Myelodysplastic Syndromes
|
June 2007 | Phase 1 |
| NCT02141477 | M.D. Anderson Cancer Center|Teva Pharmaceuticals USA |
Leukemia
|
May 6, 2015 | Phase 1 |
| NCT04752527 | The First Affiliated Hospital of Soochow University |
Acute Myeloid Leukemia, Adult
|
February 20, 2021 | Phase 2 |
| NCT00867672 | University Hospital Freiburg |
Acute Myeloid Leukemia
|
August 2011 | Phase 2 |
| NCT03969446 | City of Hope Medical Center|National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia|Recurrent Myelodysplastic Syndrome|Refractory Acute Myeloid Leukemia|Refractory Myelodysplastic Syndrome
|
May 4, 2020 | Phase 1 |
| NCT05230368 | ANRS, Emerging Infectious Diseases|INSERM SC10-US19 |
HIV-1-infection, Subtype b
|
April 15, 2022 | Phase 1 |
| NCT04123392 | Nanfang Hospital of Southern Medical University|Peking University People´s Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Third Affiliated Hospital, Sun Yat-Sen University|Zhujiang Hospital |
TP53|Myeloid Tumors|Conditioning|Allogeneic Hematopoietic Stem Cell Transplantation
|
October 2019 | Phase 2|Phase 3 |
| NCT04874480 | M.D. Anderson Cancer Center |
Recurrent Leukemia|Refractory Leukemia
|
September 27, 2021 | Phase 1 |
| NCT04655755 | M.D. Anderson Cancer Center|Astex Pharmaceuticals, Inc.|Genentech, Inc. |
Chronic Myelomonocytic Leukemia|Myelodysplastic Syndrome
|
January 19, 2021 | Phase 1|Phase 2 |
| NCT03346642 | Chinese PLA General Hospital |
Primary Mediastinal Large B-cell Lymphoma
|
May 1, 2017 | Phase 1|Phase 2 |
| NCT00054431 | National Cancer Institute (NCI) |
Accelerated Phase Chronic Myelogenous Leukemia|Blastic Phase Chronic Myelogenous Leukemia|Childhood Chronic Myelogenous Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Relapsing Chronic Myelogenous Leukemia
|
January 2003 | Phase 2 |
| NCT03263936 | Therapeutic Advances in Childhood Leukemia Consortium |
Acute Myelogenous Leukemia
|
July 11, 2017 | Phase 1 |
| NCT03828084 | EpiDestiny, Inc. |
Healthy
|
April 3, 2019 | Phase 1 |
| NCT03295552 | Shanghai Jiao Tong University School of Medicine |
Breast Neoplasm
|
November 15, 2017 | Phase 2 |
| NCT00619099 | Eisai Inc. |
Myelodysplastic Syndrome
|
May 2008 | Phase 2 |
| NCT05222984 | City of Hope Medical Center|National Cancer Institute (NCI) |
Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
|
July 29, 2022 | Phase 1 |
| NCT01455506 | Hackensack Meridian Health |
Acute Myeloid Leukemia|Myelodysplastic Syndrome
|
May 2009 | Phase 1 |
| NCT00703300 | National Cancer Institute (NCI) |
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
June 2008 | Phase 1 |
| NCT00416598 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Acute Myeloid Leukemia With Myelodysplasia-Related Changes|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A|Untreated Adult Acute Myeloid Leukemia
|
November 15, 2006 | Phase 2 |
| NCT03252457 | Shandong University|Second Affiliated Hospital of Medical College Shandong University|Shandong Provincial Hospital|Qingdao Central Hospital|Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Purpura, Thrombocytopenic, Idiopathic|Immune Thrombocytopenia
|
September 1, 2018 | Phase 3 |
| NCT01720225 | M.D. Anderson Cancer Center |
Leukemia
|
November 6, 2012 | Phase 2 |
| NCT01165996 | Case Comprehensive Cancer Center |
Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndromes|Myelodysplastic Syndromes|Refractory Anemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Ringed Sideroblasts|Refractory Cytopenia With Multilineage Dysplasia|Thrombocytopenia
|
July 2010 | Phase 1|Phase 2 |
| NCT03941964 | AbbVie |
Acute Myeloid Leukemia (AML)|Cancer
|
August 15, 2019 | Phase 3 |
| NCT03250962 | Chinese PLA General Hospital |
Hodgkin Lymphoma
|
September 11, 2017 | Phase 2 |
| NCT01993641 | Helsinn Healthcare SA |
Myelodysplastic Syndrome|MDS
|
December 2013 | Phase 2 |
| NCT01729845 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia
|
December 20, 2012 | Phase 1|Phase 2 |
| NCT03080766 | The University of Hong Kong|Janssen, LP |
Acute Myeloid Leukemia|Complex Karyotype
|
March 1, 2017 | Phase 2 |
| NCT01593670 | Masonic Cancer Center, University of Minnesota|Mayo Clinic |
Myelodysplastic Syndrome
|
March 2013 | Phase 2 |
| NCT03017131 | Roswell Park Cancer Institute|National Cancer Institute (NCI) |
Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma
|
December 8, 2017 | Phase 1 |
| NCT03026842 | The First Hospital of Jilin University|The Second Affiliated Hospital of Dalian Medical University|Second Hospital of Jilin University|Jilin University |
Acute Myeloid Leukemia
|
January 2017 | Phase 4 |
| NCT02129101 | Mayo Clinic|National Cancer Institute (NCI) |
Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndrome|Essential Thrombocythemia|Myelodysplastic Syndrome|Myelodysplastic+Myeloproliferative Neoplasm|Polycythemia Vera|Previously Treated Myelodysplastic Syndrome|Primary Myelofibrosis|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
May 2014 | Phase 1 |
| NCT04087967 | The First Affiliated Hospital of Soochow University|Second Affiliated Hospital of Soochow University|Changzhou No.2 People´s Hospital|The First People´s Hospital of Lianyungang|Jingjiang People´s Hospital|Zhangjiagang First People´s Hospital|The Second People´s Hospital of Huai´an|The Third People´s Hospital of Kunshan |
Acute Myeloid Leukemia|Induction Chemotherapy
|
April 1, 2019 | Phase 3 |
| NCT02029417 | Roswell Park Cancer Institute|National Cancer Institute (NCI)|Teva Pharmaceutical Industries, Ltd. |
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
July 2014 | Phase 2 |
| NCT02076191 | John Mascarenhas|Myeloproliferative Disorders-Research Consortium|National Cancer Institute (NCI)|Incyte Corporation|Icahn School of Medicine at Mount Sinai |
Myeloproliferative Neoplasms
|
February 2014 | Phase 1|Phase 2 |
| NCT04905810 | Brian Jonas|AbbVie|National Cancer Institute (NCI)|University of California, Davis |
Acute Myeloid Leukemia|Recurrent Acute Myeloid Leukemia
|
February 9, 2022 | Phase 2 |
| NCT01685515 | Yogen Saunthararajah|University of Illinois at Chicago|The Cleveland Clinic |
Sickle Cell Disease
|
August 2012 | Phase 1 |
| NCT05007873 | M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Astex Pharmaceuticals, Inc. |
Chronic Phase Chronic Myelogenous Leukemia|Philadelphia Chromosome Positive|BCR-ABL1 Positive Chronic Myelogenous Leukemia|BCR-ABL1 Positive
|
October 21, 2021 | Phase 2 |
| NCT00282399 | Eisai Inc. |
Myelodysplastic Syndrome
|
October 2006 | Phase 1 |
| NCT04277442 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia
|
February 6, 2020 | Phase 1 |
| NCT01882660 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
Colon Cancer
|
July 2013 | Not Applicable |
| NCT02073838 | Sarit Assouline|Jewish General Hospital |
Acute Myeloid Leukemia
|
May 2015 | Phase 2 |
| NCT01794702 | M.D. Anderson Cancer Center |
Leukemia
|
February 20, 2013 | Phase 1|Phase 2 |
| NCT05177731 | Chen Suning|The First Affiliated Hospital of Soochow University |
AML, Adult|Chemotherapy Effect
|
March 1, 2022 | Phase 3 |
| NCT05456269 | Race Oncology Ltd|Astex Pharmaceuticals, Inc. |
Acute Myeloid Leukemia|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia|Higher Risk Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia
|
July 2022 | Phase 1 |
| NCT02269280 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
October 13, 2014 | Phase 2 |
| NCT02272478 | Cardiff University|Cancer Research UK |
Acute Myeloid Leukaemia|Myelodysplastic Syndrome
|
October 30, 2014 | Phase 2|Phase 3 |
| NCT00882102 | M.D. Anderson Cancer Center|Eisai Inc. |
Acute Myelogenous Leukemia|Myelodysplastic Syndrome
|
April 2009 | Phase 2 |
| NCT05449899 | Nanfang Hospital of Southern Medical University|Peking University People´s Hospital|Institute of Hematology and Blood Diseases Hospital|Guangzhou First People´s Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|First People´s Hospital of Chenzhou|The Seventh Affiliated Hospital of Sun Yat-sen University |
Secondary Acute Myeloid Leukemia Evolving From MDS|Allogeneic Hematopoietic Stem Cell Transplantation|Conditioning
|
July 2022 | Phase 2|Phase 3 |
| NCT02109744 | University of Rochester |
Acute Myelogenous Leukemia
|
March 2014 | Phase 1|Phase 2 |
| NCT02698124 | Ulsan University Hospital|The Korean Society of Hematology, AML+MDS Working Party |
Acute Myeloid Leukemia|Elderly|Intensive Chemotherapy Unfit
|
March 2016 | |
| NCT03709550 | Roswell Park Cancer Institute |
Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|Metastatic Prostate Carcinoma in the Soft Tissue|Prostate Carcinoma Metastatic in the Bone|PSA Level Greater Than or Equal to Two|PSA Progression|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8
|
April 15, 2021 | Phase 1|Phase 2 |
| NCT01420926 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Therapy-Related Acute Myeloid Leukemia
|
November 16, 2011 | Phase 2 |
| NCT00358644 | Eisai Inc. |
Acute Myeloid Leukemia
|
March 2005 | Phase 2 |
| NCT04476199 | Gruppo Italiano Trapianto di Midollo Osseo |
Acute Myeloid Leukemia
|
December 9, 2019 | Phase 2 |
| NCT01812252 | Fred Hutchinson Cancer Center |
Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndrome|Myelodysplastic Syndrome|Secondary Myelodysplastic Syndrome
|
April 2, 2013 | Phase 2 |
| NCT05037500 | Roswell Park Cancer Institute|National Comprehensive Cancer Network |
Castration-Resistant Prostate Carcinoma|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8
|
January 26, 2022 | Phase 1 |
| NCT01786343 | M.D. Anderson Cancer Center |
Leukemia
|
February 5, 2013 | Phase 2 |
| NCT00760084 | Eisai Inc. |
Acute Myelogenous Leukemia|Myelodysplastic Syndrome
|
July 2005 | Phase 2 |
| NCT01130506 | National Cancer Institute (NCI) |
Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
May 17, 2010 | Phase 1 |
| NCT04337606 | Chinese PLA General Hospital |
Non Hodgkin Lymphoma
|
April 4, 2020 | Phase 1|Phase 2 |
| NCT02564536 | Washington University School of Medicine|CTI BioPharma |
Chronic Myelomonocytic Leukemia|Juvenile Myelomonocytic Leukemia|Atypical Chronic Myeloid Leukemia|Myeloproliferative Neoplasm|Myelodysplastic Syndromes|Myelofibrosis
|
June 2017 | Phase 1 |
| NCT05453552 | Nanfang Hospital of Southern Medical University|Peking University People´s Hospital|Institute of Hematology and Blood Diseases Hospital|Guangzhou First People´s Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|First People´s Hospital of Chenzhou|The Seventh Affiliated Hospital of Sun Yat-sen University |
Myelodysplastic Syndrome|Allogeneic Hematopoietic Stem Cell Transplantation|Conditioning
|
July 2022 | Phase 2|Phase 3 |
| NCT00321711 | Amgen |
MDS|Myelodysplastic Syndromes|Thrombocytopenia
|
October 1, 2006 | Phase 2 |
| NCT00000623 | HealthCore-NERI|National Heart, Lung, and Blood Institute (NHLBI)|Thalassemia Clinical Research Network |
Anemia, Cooley´s|Beta-Thalassemia|Hematologic Diseases|Thalassemia|Osteoporosis|Iron Overload|Hypertension, Pulmonary
|
July 2000 | |
| NCT00113321 | M.D. Anderson Cancer Center|Eisai Inc. |
Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia
|
March 2005 | Phase 2 |
| NCT01829503 | Annie Im, M.D.|University of Pittsburgh |
Acute Myeloid Leukemia
|
February 2013 | Phase 2 |
| NCT04510610 | Chinese PLA General Hospital |
Hodgkin Lymphoma
|
September 1, 2019 | Phase 2|Phase 3 |
| NCT01177540 | Eisai Inc. |
Pediatric Acute Myelogenous Leukemia (AML)
|
March 3, 2011 | Phase 2 |
| NCT01798901 | Alison Walker|Ohio State University Comprehensive Cancer Center |
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
September 17, 2013 | Phase 1 |
| NCT01893320 | M.D. Anderson Cancer Center|Sunesis Pharmaceuticals |
Leukemia
|
July 18, 2013 | Phase 1|Phase 2 |
| NCT02159820 | Chinese PLA General Hospital |
Primary Malignant Neoplasm of Ovary|FIGO Stages II to IV
|
June 2014 | Phase 2|Phase 3 |
| NCT03132454 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia
|
July 25, 2017 | Phase 1 |
| NCT05184842 | Montefiore Medical Center |
MDS|AML
|
March 23, 2022 | Phase 2 |
| NCT03844815 | University of Chicago|AbbVie |
Acute Myeloid Leukemia
|
November 18, 2019 | Phase 1 |
| NCT02010645 | M.D. Anderson Cancer Center|GlaxoSmithKline |
Leukemia
|
March 2014 | Phase 2 |
| NCT02685228 | The First Hospital of Jilin University |
Pancreatic Cancer
|
March 2016 | Not Applicable |
| NCT01001143 | Washington University School of Medicine |
Leukemia, Myeloid, Acute
|
May 2010 | Phase 1 |
| NCT02316028 | Universitair Ziekenhuis Brussel|Janssen, LP |
Liver Metastasis|Colorectal Cancer
|
March 2014 | Phase 1|Phase 2 |
| NCT03303339 | Cardiff Oncology |
Acute Myeloid Leukemia
|
November 17, 2017 | Phase 1|Phase 2 |
| NCT05272384 | National Cancer Institute (NCI) |
Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Hodgkin Lymphoma
|
June 30, 2022 | Phase 1 |
| NCT03793517 | Peking University People´s Hospital |
Stem Cell Transplant Complications|Leukemia, Myeloid, Acute|Leukemia Relapse
|
September 1, 2018 | Phase 2|Phase 3 |
| NCT03701451 | Wei Jiang|Guilin Hospital of Traditional Chinese Medicine|Guilin Medical University, China |
Nasopharyngeal Carcinoma
|
February 28, 2018 | Phase 1|Phase 2 |
| NCT04730258 | Treadwell Therapeutics, Inc |
Acute Myeloid Leukemia|Myelodysplastic Syndromes|Chronic Myelomonocytic Leukemia|AML|MDS|CMML
|
April 16, 2021 | Phase 1|Phase 2 |
| NCT05143125 | Shenzhen University General Hospital |
Malignancy
|
February 5, 2021 | Phase 1|Phase 2 |
| NCT02412475 | Michael Burke|Children´s Hospitals and Clinics of Minnesota|Medical College of Wisconsin |
Leukemia, Acute Myeloid
|
February 21, 2015 | Phase 1 |
| NCT01483690 | Therapeutic Advances in Childhood Leukemia Consortium |
Acute Lymphoblastic Leukemia|Precursor B-Cell Lymphoblastic Leukemia|Precursor T-Cell Lymphoblastic Leukemia
|
December 2011 | Phase 1|Phase 2 |
| NCT01515527 | M.D. Anderson Cancer Center |
Leukemia
|
February 7, 2012 | Phase 2 |
| NCT01303796 | Cyclacel Pharmaceuticals, Inc. |
Acute Myeloid Leukemia
|
October 1, 2011 | Phase 3 |
| NCT01211457 | Cyclacel Pharmaceuticals, Inc.|M.D. Anderson Cancer Center |
Acute Myeloid Leukemia|Myelodysplastic Syndromes
|
June 17, 2010 | Phase 1|Phase 2 |
| NCT04657081 | Astex Pharmaceuticals, Inc. |
Acute Myeloid Leukemia
|
February 9, 2021 | Phase 1|Phase 2 |
| NCT04187703 | Benjamin Tomlinson|Case Comprehensive Cancer Center |
Myelodysplastic Syndromes|MDS+MPN Crossover Syndromes
|
November 16, 2020 | Early Phase 1 |
| NCT00067808 | M.D. Anderson Cancer Center|Eisai Inc. |
Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia
|
October 2003 | Phase 2 |
| NCT03041688 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia
|
October 12, 2017 | Phase 1 |
| NCT00109824 | National Cancer Institute (NCI) |
Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Mantle Cell Lymphoma
|
March 2006 | Phase 1 |
| NCT04493099 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
|
October 2020 | Phase 1|Phase 2 |
| NCT00538876 | Weill Medical College of Cornell University|Eisai Inc. |
Acute Myeloid Leukemia
|
July 2007 | Phase 1 |
| NCT00968071 | M.D. Anderson Cancer Center |
Acute Myelogenous Leukemia|Myelodysplastic Syndrome
|
February 2008 | Phase 2 |
| NCT04098653 | Nanfang Hospital of Southern Medical University|Peking University People´s Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Third Affiliated Hospital, Sun Yat-Sen University|Zhujiang Hospital |
Allogeneic Hematopoietic Stem Cell Transplantation|Conditioning|Myeloid Tumors
|
September 2019 | Phase 2|Phase 3 |
| NCT04582604 | Chinese PLA General Hospital |
Peripheral Blood Stem Cell Transplantation
|
September 1, 2020 | Phase 1|Phase 2 |
| NCT03467178 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
Recurrent, Platinum-resistant Ovarian Cancer
|
July 30, 2018 | Phase 2 |
| NCT00084981 | National Cancer Institute (NCI) |
Recurrent Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer
|
April 2004 | Phase 1 |
| NCT02084563 | Hospital Israelita Albert Einstein |
Acute Myeloid Leukemia|Myeloproliferative Neoplasms|Myelodysplastic Syndromes|Myeloproliferative+Myelodysplastic Neoplasm
|
October 2012 | Phase 2 |
| NCT02846935 | Yogen Saunthararajah|Case Comprehensive Cancer Center |
T-cell Lymphoma|Aggressive B-cell Lymphoma|Non-Hodgkin´s Lymphomas|Indolent B-cell Lymphoma
|
April 25, 2017 | Early Phase 1 |
| NCT03926624 | Delta-Fly Pharma, Inc. |
Leukemia, Myeloid, Acute
|
November 22, 2019 | Phase 3 |
| NCT02488408 | BerGenBio ASA |
Acute Myeloid Leukemia|Myelodysplastic Syndromes
|
September 2014 | Phase 1|Phase 2 |
| NCT03009240 | City of Hope Medical Center|National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
August 21, 2017 | Phase 1 |
| NCT04025593 | Ruijin Hospital |
Diffuse Large B Cell Lymphoma
|
July 17, 2019 | Phase 2 |
| NCT01251627 | Fondazione Italiana Sindromi Mielodisplastiche-ETS|Centro di Riferimento per l´Epidemiologia e la Prev. Oncologica Piemonte |
Chronic Myelomonocytic Leukemia
|
April 2010 | Phase 2 |
| NCT03256071 | The First Affiliated Hospital of Soochow University|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Jiangsu University|Xuzhou Medical University|Southeast University, China |
Acute Myeloid Leukemia|Allogeneic Hematopoietic Stem Cell Transplantation|Conditioning
|
September 2017 | Phase 2|Phase 3 |
| NCT03687463 | Capital Research Institute of Pediatrics |
Hematopoietic System--Cancer
|
April 10, 2015 | |
| NCT00075010 | M.D. Anderson Cancer Center|Eisai Inc. |
Leukemia|Myelodysplastic Syndromes
|
January 23, 2004 | Phase 1|Phase 2 |
| NCT01707004 | University of Wisconsin, Madison|National Cancer Institute (NCI) |
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia
|
May 16, 2013 | Phase 2 |
| NCT03404193 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Blastic Plasmacytoid Dendritic Cell Neoplasm|Chronic Myelomonocytic Leukemia|Mixed Phenotype Acute Leukemia|Myelodysplastic Syndrome|Recurrent Acute Biphenotypic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm|Recurrent Chronic Myelomonocytic Leukemia|Recurrent Mixed Phenotype Acute Leukemia|Refractory Acute Myeloid Leukemia|Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm|Refractory Chronic Myelomonocytic Leukemia|Refractory Mixed Phenotype Acute Leukemia
|
January 18, 2018 | Phase 2 |
| NCT00085293 | National Cancer Institute (NCI) |
Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer
|
May 2004 | Phase 2 |
| NCT00089089 | National Cancer Institute (NCI) |
Hematopoietic+Lymphoid Cancer|Unspecified Adult Solid Tumor, Protocol Specific
|
September 2004 | Phase 1 |
| NCT02085408 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
December 28, 2010 | Phase 3 |
| NCT01633099 | Jianxiang Wang|Xian-Janssen Pharmaceutical Ltd.|Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Untreated Adult Acute Myeloid Leukemia|Effect of Drugs|Drug Safety
|
May 2012 | Phase 3 |
| NCT05190471 | Bio-Path Holdings, Inc. |
Acute Myeloid Leukemia, in Relapse|Acute Myeloid Leukemia Refractory
|
August 16, 2022 | Phase 1 |
| NCT00079378 | National Cancer Institute (NCI) |
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Myeloid Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Untreated Adult Acute Myeloid Leukemia
|
February 2004 | Phase 1 |
| NCT04655391 | City of Hope Medical Center|National Cancer Institute (NCI) |
Recurrent Acute Myeloid Leukemia
|
June 25, 2022 | Phase 1 |
| NCT02781883 | Bio-Path Holdings, Inc. |
Acute Myeloid Leukemia (AML)
|
May 2016 | Phase 2 |
| NCT01546038 | Pfizer |
Acute Myeloid Leukemia
|
June 27, 2012 | Phase 2 |
| NCT03063944 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Otsuka America Pharmaceutical|Thomas Jefferson University |
Acute Myeloid Leukemia|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
|
March 17, 2017 | Phase 1 |
| NCT04055844 | Masonic Cancer Center, University of Minnesota|Incyte Corporation |
Acute Myeloid Leukemia|Myeloid and Monocytic Leukemia|Myelodysplastic Syndromes
|
February 17, 2020 | Phase 2 |
| NCT00275080 | National Cancer Institute (NCI) |
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Blastic Phase Chronic Myelogenous Leukemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Secondary Acute Myeloid Leukemia|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia
|
February 2006 | Phase 1 |
| NCT02634827 | Mayo Clinic|National Cancer Institute (NCI) |
Acute Myeloid Leukemia With FLT3+ITD Mutation|Acute Myeloid Leukemia With Gene Mutations|FLT3 Tyrosine Kinase Domain Point Mutation|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
December 30, 2015 | Phase 2 |
| NCT05524857 | Joseph Jurcic|Bristol-Myers Squibb|Columbia University |
Myeloproliferative Neoplasm
|
September 2022 | Phase 1 |
| NCT05455294 | Jacqueline Garcia, MD|AbbVie|Dana-Farber Cancer Institute |
Myeloid Malignancy|Myelodysplastic Syndromes|Myelofibrosis|Acute Myeloid Leukemia|Myeloproliferative Neoplasm
|
July 18, 2022 | Phase 1 |
| NCT00382200 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Myelodysplastic Syndromes
|
July 2006 | Phase 1|Phase 2 |
| NCT03679650 | Dana-Farber Cancer Institute|National Cancer Institute (NCI) |
Acute Myelogenous Leukemia
|
October 11, 2018 | Phase 1 |
| NCT01352650 | Weill Medical College of Cornell University|Genzyme, a Sanofi Company |
Acute Myeloid Leukemia
|
June 17, 2011 | Phase 1 |
| NCT01627041 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Adult Acute Basophilic Leukemia|Adult Acute Monoblastic Leukemia|Adult Acute Monocytic Leukemia|Adult Acute Myeloid Leukemia With Maturation|Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL|Adult Acute Myeloid Leukemia Without Maturation|Adult Acute Myelomonocytic Leukemia|Alkylating Agent-Related Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia
|
September 16, 2011 | Phase 2 |
| NCT05320640 | Chinese PLA General Hospital |
Relapsed+Refractory Non-Hodgkin Lymphoma|Advanced Solid Tumors
|
March 30, 2022 | Phase 1|Phase 2 |
| NCT04233294 | Chinese PLA General Hospital |
Hodgkin Lymphoma
|
February 2, 2020 | Phase 2 |
| NCT00801489 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1|de Novo Myelodysplastic Syndrome|High Risk Myelodysplastic Syndrome|Inv(16)|Myelodysplastic Syndrome With Excess Blasts|t(16;16)|t(8;21)|Untreated Adult Acute Myeloid Leukemia
|
April 4, 2007 | Phase 2 |
| NCT05351346 | Ruijin Hospital |
Diffuse Large B Cell Lymphoma
|
June 1, 2022 | Phase 3 |
| NCT04076137 | Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.|Shenzhen Second People´s Hospital |
Malignant Solid Tumor
|
May 1, 2019 | Early Phase 1 |
| NCT02650986 | Roswell Park Cancer Institute|National Cancer Institute (NCI) |
Advanced Fallopian Tube Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Melanoma|Advanced Ovarian Carcinoma|Advanced Primary Peritoneal Carcinoma|Advanced Synovial Sarcoma|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Metastatic Fallopian Tube Carcinoma|Metastatic Melanoma|Metastatic Ovarian Carcinoma|Metastatic Primary Peritoneal Carcinoma|Metastatic Synovial Sarcoma|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Ovarian Carcinoma|Platinum-Resistant Primary Peritoneal Carcinoma|Stage III Fallopian Tube Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Primary Peritoneal Cancer AJCC v8|Stage IIIA Fallopian Tube Cancer AJCC v8|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA Primary Peritoneal Cancer AJCC v8|Stage IIIA1 Fallopian Tube Cancer AJCC v8|Stage IIIA1 Ovarian Cancer AJCC v8|Stage IIIA2 Fallopian Tube Cancer AJCC v8|Stage IIIA2 Ovarian Cancer AJCC v8|Stage IIIB Fallopian Tube Cancer AJCC v8|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIB Primary Peritoneal Cancer AJCC v8|Stage IIIC Fallopian Tube Cancer AJCC v8|Stage IIIC Ovarian Cancer AJCC v8|Stage IIIC Primary Peritoneal Cancer AJCC v8|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8|Stage IVA Fallopian Tube Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Primary Peritoneal Cancer AJCC v8|Stage IVB Fallopian Tube Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Primary Peritoneal Cancer AJCC v8|Unresectable Melanoma|Unresectable Ovarian Carcinoma|Unresectable Synovial Sarcoma
|
July 14, 2017 | Phase 1|Phase 2 |
| NCT01378416 | Eisai Inc. |
Leukemia
|
April 2005 | Phase 1 |
| NCT01130662 | University of Kansas|Novartis|University of Kansas Medical Center |
Acute Myeloid Leukemia
|
March 2010 | Phase 1 |
| NCT05403450 | Astex Pharmaceuticals, Inc. |
Relapsed+Refractory Peripheral T-cell Lymphoma
|
June 23, 2022 | Phase 1|Phase 2 |
| NCT04097470 | Stichting Hemato-Oncologie voor Volwassenen Nederland|Swiss Group for Clinical Cancer Research |
AML+MDS
|
December 5, 2019 | Phase 2 |
| NCT03358719 | Roswell Park Cancer Institute|Celldex Therapeutics |
Acute Myeloid Leukemia|Blasts 30 Percent or Less of Bone Marrow Nucleated Cells|Chronic Myelomonocytic Leukemia|High Risk Myelodysplastic Syndrome|Myelodysplastic Syndrome|Refractory Anemia
|
March 27, 2018 | Phase 1 |
| NCT00260065 | Eisai Inc. |
Myelodysplastic Syndrome
|
May 2005 | Phase 2 |
| NCT03593915 | Sumitomo Pharma Oncology, Inc. |
Myelodysplastic Syndromes (MDS)
|
August 29, 2018 | Phase 1|Phase 2 |
| NCT02957968 | Virginia Commonwealth University|Merck Sharp & Dohme LLC|National Cancer Institute (NCI) |
Breast Adenocarcinoma|Estrogen Receptor- Negative Breast Cancer|Estrogen Receptor-positive Breast Cancer|HER2+Neu Negative|Invasive Breast Carcinoma|Progesterone Receptor Negative|Progesterone Receptor Positive Tumor|Stage II Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Triple-negative Breast Carcinoma
|
January 24, 2017 | Phase 2 |
| NCT04086238 | EpiDestiny, Inc. |
Healthy
|
October 8, 2019 | Phase 1 |
| NCT00398983 | M.D. Anderson Cancer Center|Eisai Inc. |
Acute Myelogenous Leukemia
|
August 2006 | Phase 2|Phase 3 |
| NCT03535753 | Beijing Immunochina Medical Science & Technology Co., Ltd. |
NHL
|
September 1, 2017 | Phase 1 |
| NCT00691938 | Washington University School of Medicine |
Leukemia, Myeloid, Acute|Myelodysplastic Syndromes
|
June 2008 | Phase 1|Phase 2 |
| NCT05564650 | Thomas Jefferson University |
Myelodysplastic Syndrome|Recurrent Myelodysplastic Syndrome|Refractory Myelodysplastic Syndrome
|
October 2022 | Phase 1|Phase 2 |
| NCT03063203 | Washington University School of Medicine|Janssen Pharmaceuticals|National Institutes of Health (NIH)|National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Acute Myeloid Leukemia, Relapsed, Adult
|
July 14, 2017 | Phase 2 |
| NCT02093403 | Bhavana Bhatnagar|Karyopharm Therapeutics Inc|Ohio State University Comprehensive Cancer Center |
Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
March 2014 | Phase 1 |
| NCT01809392 | The First Affiliated Hospital of Soochow University|Xian-Janssen Pharmaceutical Ltd. |
Acute Myelocytic Leukemia|Myelodysplastic Syndromes
|
January 2013 | Phase 2|Phase 3 |
| NCT01751867 | Xian-Janssen Pharmaceutical Ltd. |
Myelodysplastic Syndrome
|
August 2009 | Phase 3 |
| NCT01853228 | Janssen Research & Development, LLC |
Acute Myeloid Leukemia
|
October 22, 2013 | Phase 1|Phase 2 |
| NCT04482621 | Johns Hopkins University |
COVID-19
|
September 14, 2020 | Phase 2 |
| NCT00030615 | National Cancer Institute (NCI) |
Male Breast Cancer|Recurrent Bladder Cancer|Recurrent Breast Cancer|Recurrent Melanoma|Stage III Melanoma|Stage IV Bladder Cancer|Stage IV Breast Cancer|Stage IV Melanoma|Unspecified Adult Solid Tumor, Protocol Specific
|
December 2001 | Phase 1 |
| NCT02878785 | University of Maryland, Baltimore|Pfizer|Van Andel Research Institute |
Acute Myeloid Leukemia
|
August 2016 | Phase 1|Phase 2 |
| NCT04292769 | Li Yu|Chinese PLA General Hospital |
Malignant Neoplasm
|
January 21, 2020 | Phase 3 |
| NCT00049582 | National Cancer Institute (NCI) |
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|de Novo Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Untreated Adult Acute Myeloid Leukemia
|
September 2002 | Phase 1 |
| NCT00986804 | Washington University School of Medicine |
Leukemia, Myeloid, Acute|Myelodysplastic Syndromes
|
December 2009 | Phase 1 |
| NCT02003573 | Boehringer Ingelheim |
Leukemia, Myeloid, Acute
|
January 29, 2014 | Phase 1 |
| NCT01876641 | Mohammed M Milhem|Genentech, Inc.|University of Iowa |
Metastatic Melanoma|Melanoma|BRAF-mutated Metastatic Melanoma|V600EBRAF-mutated Metastatic Melanoma
|
October 2013 | Phase 1 |
| NCT00002831 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
August 1, 1995 | Phase 1|Phase 2 |
| NCT00715793 | Hussein Tawbi|Eisai Inc.|Schering-Plough|University of Pittsburgh |
Malignant Melanoma
|
June 2008 | Phase 1|Phase 2 |
| NCT00866073 | University Hospital Freiburg |
Acute Myeloid Leukemia
|
April 2003 | Phase 2 |
| NCT03799224 | Peking University People´s Hospital |
Stem Cell Transplant Complications|Relapse Leukemia|Refractory Leukemia
|
December 1, 2018 | Phase 2|Phase 3 |
| NCT02847000 | Yogen Saunthararajah|Case Comprehensive Cancer Center |
Metastatic Pancreatic Adenocarcinoma
|
December 20, 2016 | Early Phase 1 |
| NCT00002832 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes
|
August 1995 | Phase 1|Phase 2 |
| NCT05010122 | M.D. Anderson Cancer Center |
Acute Myeloid Leukemia|Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
|
July 8, 2021 | Phase 1|Phase 2 |
| NCT01806116 | The First Affiliated Hospital of Soochow University |
Higher-risk Myelodysplastic Syndrome|Relapsed +Refractory Acute Myeloid Leukemia
|
September 2009 | Phase 4 |
| NCT03066648 | Novartis Pharmaceuticals|Novartis |
Leukemia|Leukemia, Myeloid|Leukemia, Myeloid, Acute|Myelodysplastic Syndromes|Preleukemia|Bone Marrow Diseases|Hematologic Diseases|Chronic Myelomonocytic Leukemia
|
July 6, 2017 | Phase 1 |
| NCT01799083 | Han weidong|Chinese PLA General Hospital |
Solid Tumors|B Cell Lymphoma
|
December 2012 | Phase 1|Phase 2 |
| NCT02664181 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lung Cancer|Non-small Cell Lung Cancer
|
June 6, 2017 | Phase 2 |
| NCT00042016 | Astex Pharmaceuticals, Inc. |
Chronic Myelogenous Leukemia
|
July 2002 | Phase 2 |
| NCT01149408 | University of Utah|Eisai Inc. |
Acute Myeloid Leukemia|AML
|
February 2011 | Phase 1 |
| NCT00903760 | M.D. Anderson Cancer Center|Genzyme, a Sanofi Company |
Myelodysplastic Syndrome
|
January 2010 | Phase 2 |
| NCT04850560 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Objective Response Rate
|
May 18, 2021 | Phase 1 |
| NCT00943553 | Eisai Inc. |
Acute Myelogenous Leukemia (AML)
|
June 2010 | Phase 2 |
| NCT02985372 | Chunyan Ji|Binzhou Medical University|Shengli Oilfield Central Hospital|Heze Municipal Hospital|Jinan Military Genaral Hospital|Jinan Central Hospital|Jining Medical University|Linyi People´s Hospital|Qingdao University|Rizhao People´s Hospital|Qianfoshan Hospital|Qilu Hospital of Shandong University (Qingdao)|Taian City Central Hospital|Taishan Medical University Affiliated Hospital|Weihai Municipal Hospital|Weifang Medical University|Zibo First Hospital|Central Hospital of Zibo|Shandong University |
Acute Myeloid Leukemia, Adult
|
December 2016 | Phase 3 |
| NCT04975919 | M.D. Anderson Cancer Center |
Recurrent Acute Biphenotypic Leukemia|Recurrent Acute Myeloid Leukemia|Refractory Acute Biphenotypic Leukemia|Refractory Acute Myeloid Leukemia
|
September 29, 2021 | Phase 2 |
| NCT00791271 | M.D. Anderson Cancer Center|Schering-Plough|Eisai Inc. |
Melanoma
|
September 2, 2008 | Phase 1 |
| NCT04146038 | Rutgers, The State University of New Jersey|National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia
|
October 26, 2020 | Phase 2 |
| NCT00042003 | Astex Pharmaceuticals, Inc.|Eisai Inc. |
Chronic Myelogenous Leukemia
|
July 2002 | Phase 2 |
| NCT03855371 | Ruijin Hospital |
P53 Mutation|Myeloid Malignancy|MDS|Aml
|
January 10, 2018 | Phase 1 |
| NCT02172872 | European Organisation for Research and Treatment of Cancer - EORTC|Janssen Pharmaceuticals|Gruppo Italiano Malattie EMatologiche dell´Adulto |
Acute Myeloid Leukemia (AML)
|
November 28, 2014 | Phase 3 |
| NCT03530085 | Nanfang Hospital of Southern Medical University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Guangzhou First People´s Hospital|Peking University People´s Hospital|Third Affiliated Hospital, Sun Yat-Sen University|Zhujiang Hospital |
Acute Myeloid Leukemia|Allogeneic Hematopoietic Stem Cell Transplantation|Conditioning|Elderly
|
June 15, 2018 | Phase 2|Phase 3 |
| NCT02996474 | National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) |
Relapsed Acute Myeloid Leukemia
|
December 16, 2016 | Phase 1|Phase 2 |
| NCT02608268 | Novartis Pharmaceuticals|Novartis |
Advanced Malignancies
|
November 23, 2015 | Phase 1|Phase 2 |
| NCT00003361 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes
|
April 1998 | Phase 2 |
| NCT05376852 | Nanfang Hospital of Southern Medical University |
Chronic Myeloid Leukemia in Myeloid Blast Crisis|Chronic Myeloid Leukaemia Transformation|Chronic Myeloid Leukemia - Accelerated Phase|Chronic Myeloid Leukemia in Lymphoid Blast Crisis (Diagnosis)
|
December 1, 2021 | Phase 2 |
| NCT03579082 | Mingzhi Zhang|Zhengzhou University |
Diffuse Large B Cell Lymphoma
|
June 1, 2018 | Phase 4 |
| NCT02785900 | Seagen Inc. |
Acute Myeloid Leukemia
|
May 2016 | Phase 3 |
| NCT04985656 | Takeda |
Myelodysplastic Syndromes (MDS)
|
October 1, 2021 | Phase 2 |
| NCT00357708 | National Cancer Institute (NCI) |
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Chronic Myelomonocytic Leukemia|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable|Philadelphia Chromosome Negative Chronic Myelogenous Leukemia|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia
|
June 2006 | Phase 1 |
| NCT01567059 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Acute Myeloid Leukemia With Multilineage Dysplasia|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Untreated Adult Acute Myeloid Leukemia
|
May 2012 | Phase 2 |
| NCT03596892 | Nanfang Hospital of Southern Medical University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Guangzhou First People´s Hospital|Peking University People´s Hospital|Zhujiang Hospital|Third Affiliated Hospital, Sun Yat-Sen University |
Allogeneic Hematopoietic Stem Cell Transplantation|Conditions|Mixed-lineage-leukemia (MLL)-Rearranged Acute Leukemia
|
July 2018 | Phase 2|Phase 3 |
| NCT04746235 | M.D. Anderson Cancer Center |
Acute Myeloid Leukemia|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
|
February 22, 2021 | Phase 2 |
| NCT02441803 | M.D. Anderson Cancer Center |
Leukemia
|
September 14, 2015 | Phase 2 |
| NCT02532010 | Weill Medical College of Cornell University |
Acute Myeloid Leukemia (AML)
|
June 15, 2015 | Phase 2 |
| NCT01498445 | M.D. Anderson Cancer Center|Bristol-Myers Squibb |
Leukemia
|
June 12, 2012 | Phase 1|Phase 2 |
| NCT00744757 | Johnson & Johnson Taiwan Ltd |
Myelodysplastic Syndrome
|
August 2008 | Phase 2 |
| NCT00037817 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Advanced Esophageal Cancers|Primary Small Cell Lung Cancers|Non-Small-Cell Lung Carcinoma|Pleural Mesotheliomas|Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura
|
May 17, 2002 | Phase 1 |
| NCT02779569 | The First Affiliated Hospital with Nanjing Medical University |
Myelodysplastic Syndromes (MDS)
|
March 2016 | Not Applicable |
| NCT02839694 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma
|
July 7, 2016 | Phase 1 |
| NCT00879385 | University of Utah|Amgen|Eisai Inc. |
Colorectal Cancer
|
December 2009 | Phase 1 |
| NCT05360264 | Luca Cardone|Anticancer Fund, Belgium|Azienda Ospedaliera Universitaria Integrata Verona|Catholic University of the Sacred Heart|Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale|San Raffaele University Hospital, Italy|University of Pisa|Regina Elena Cancer Institute |
Pancreatic Adenocarcinoma Metastatic|Pancreatic Adenocarcinoma Recurrent
|
January 15, 2022 | Phase 2 |
| NCT03875287 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Astex Pharmaceuticals, Inc. |
Solid Tumor
|
April 17, 2019 | Phase 1 |
| NCT04282187 | University of Washington |
Acute Myeloid Leukemia|Essential Thrombocythemia|Myelodysplastic Syndrome|Myelodysplastic+Myeloproliferative Neoplasm|Myeloproliferative Neoplasm|Myeloproliferative Neoplasm, Unclassifiable|Polycythemia Vera|Primary Myelofibrosis|Secondary Myelofibrosis
|
March 24, 2020 | Phase 2 |
| NCT03146871 | University of Southern California|National Cancer Institute (NCI) |
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Previously Treated Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes|Recurrent Adult Acute Myeloid Leukemia
|
April 20, 2017 | Phase 2 |
| NCT05265962 | The First Affiliated Hospital of Zhengzhou University |
Esophageal Squamous Cell Carcinoma
|
December 1, 2022 | Phase 2 |
| NCT02264873 | University of Florida|Hyundai Hope On Wheels |
Leukemia, Lymphoblastic, Acute|Leukemia, Myeloid Acute|Hematopoetic Myelodysplasia
|
October 2014 | Phase 1 |
| NCT01607645 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts
|
July 2012 | Phase 2 |
| NCT02323607 | Bhavana Bhatnagar|CTI BioPharma|Ohio State University Comprehensive Cancer Center |
Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
January 12, 2016 | Phase 1 |
| NCT00043134 | European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms
|
May 2002 | Phase 3 |
| NCT02890329 | National Cancer Institute (NCI) |
Previously Treated Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia|Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes|Recurrent Myelodysplastic Syndrome|Refractory Acute Myeloid Leukemia|Refractory Myelodysplastic Syndrome|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndrome
|
April 14, 2017 | Phase 1 |
| NCT05148234 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Myelodysplastic Syndromes
|
November 27, 2022 | Phase 1|Phase 2 |
| NCT04774393 | M.D. Anderson Cancer Center |
Acute Myeloid Leukemia|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
|
May 24, 2021 | Phase 1|Phase 2 |
| NCT01628471 | Uman Pharma|DSM Nutritional Products, Inc.|MDEIE Ministry, Québec Government|INRS-Institut Armand Frappier , Université du Québec |
Non Small Cell Lung Cancer
|
November 2012 | Phase 1|Phase 2 |
| NCT00701298 | National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
April 2009 | Phase 1 |
| NCT02332889 | University of Louisville |
Gliomas|Medulloblastoma|Neuroectodermal Tumors, Primitive
|
April 2015 | Phase 1|Phase 2 |
| NCT00561912 | M.D. Anderson Cancer Center|Eisai Inc. |
Renal Cell Carcinoma
|
October 2007 | Phase 2 |
| NCT03240211 | University of Virginia|Merck Sharp & Dohme LLC|Otsuka Pharmaceutical Development & Commercialization, Inc. |
PTCL|CTCL
|
February 2, 2022 | Phase 1 |
| NCT03019003 | Massachusetts General Hospital|AstraZeneca|Astex Pharmaceuticals, Inc. |
Head and Neck Cancer
|
March 20, 2017 | Phase 1|Phase 2 |
| NCT00095784 | National Cancer Institute (NCI) |
Primary Myelofibrosis|Secondary Myelofibrosis
|
September 29, 2004 | Phase 2 |
| NCT01333449 | Singapore General Hospital|Johnson & Johnson |
Myelodysplastic Syndrome
|
July 2010 | Phase 2 |
| NCT05201066 | Novartis Pharmaceuticals|Novartis |
Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic
|
November 1, 2022 | Phase 2 |
| NCT04446130 | The First Affiliated Hospital of Soochow University|Henan Cancer Hospital|Shandong Provincial Hospital|Shenzhen People´s Hospital|The First Affiliated Hospital of Anhui Medical University|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Changzhou No.2 People´s Hospital|The Second People´s Hospital of Huai´an |
Induction Chemotherapy|Acute T-Lymphocytic Leukemia|T-cell Lymphoblastic Lymphoma Leukemia|T-cell+Myeloid Mixed Phenotype Acute Leukemia
|
January 1, 2019 | Phase 3 |
| NCT03417427 | Xuejie Jiang|Nanfang Hospital of Southern Medical University |
Leukemia, Myeloid
|
February 1, 2018 | Phase 2 |
| NCT02744742 | Nanfang Hospital of Southern Medical University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Institute of Hematology and Blood Diseases Hospital|Peking University People´s Hospital|First People´s Hospital of Chenzhou|Liuzhou Workers Hospital |
Myelodysplastic Syndrome|Allogeneic Hematopoietic Stem Cell Transplantation|Conditioning
|
April 18, 2016 | Phase 2|Phase 3 |
| NCT00043381 | Astex Pharmaceuticals, Inc. |
Myelodysplastic Syndrome
|
April 2001 | Phase 3 |
| NCT00349596 | M.D. Anderson Cancer Center|Eisai Inc. |
Acute Lymphocytic Leukemia
|
July 2006 | Phase 1 |
| NCT02343939 | Gilead Sciences |
Acute Myeloid Leukemia
|
July 1, 2015 | Phase 1|Phase 2 |
| NCT03113071 | Fox Chase Cancer Center |
Acute Myeloid Leukemia|Myelodysplastic Syndromes
|
June 2, 2017 | Phase 1|Phase 2 |
| NCT02214407 | Groupe Francophone des Myelodysplasies|Janssen-Cilag Ltd. |
MDS
|
October 14, 2014 | Phase 3 |
| NCT02013102 | Cttq |
Myelodysplastic Syndrome
|
March 2013 | Phase 4 |
| NCT03356080 | Shanghai Tong Ren Hospital |
Acute Myeloid Leukemia|Myelodysplastic Syndrome
|
July 7, 2017 | Phase 2 |
| NCT05382390 | Huihan Wang|Shengjing Hospital |
Acute Myeloid Leukemia
|
January 21, 2022 | Phase 3 |
| NCT03553537 | Southwest Hospital, China |
Peripheral T-cell Lymphoma
|
June 2018 | Phase 3 |
| NCT04878432 | Novartis Pharmaceuticals|Novartis |
Myelodysplastic Syndrome (MDS)
|
March 17, 2022 | Phase 2 |
| NCT03045510 | Shandong University |
Myelodysplastic Syndromes
|
December 1, 2016 | Phase 2 |
| NCT02499861 | St. Justine´s Hospital |
Cancer
|
July 2015 | Phase 1|Phase 2 |
| NCT00828802 | Duke University|Celgene Corporation |
Myelodysplastic Syndromes
|
March 2009 | Phase 1 |
| NCT00002980 | California Cancer Consortium|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous Condition|Unspecified Adult Solid Tumor, Protocol Specific
|
May 1997 | Phase 1 |
| NCT01568333 | Shandong University|Qingdao University|Shandong Provincial Hospital |
Immune Thrombocytopenia
|
August 2015 | Phase 2 |
| NCT01011283 | Eisai Inc. |
Myelodysplastic Syndromes
|
November 2009 | Phase 4 |
| NCT02632721 | Boehringer Ingelheim |
Leukemia, Myeloid, Acute
|
June 16, 2016 | Phase 1|Phase 2 |
| NCT00886457 | Nevada Cancer Institute|National Institutes of Health (NIH)|Schering-Plough |
Cancer
|
April 2009 | Phase 1 |
| NCT03226418 | University of Nebraska|National Cancer Institute (NCI) |
Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia
|
July 7, 2017 | Phase 2 |
| NCT00477386 | Indiana University|Eisai Inc. |
Ovarian Cancer
|
July 2007 | Phase 1|Phase 2 |
| NCT00414310 | M.D. Anderson Cancer Center|Eisai Inc. |
Myelodysplastic Syndrome|Acute Myelogenous Leukemia
|
December 2006 | Phase 2 |
| NCT02662647 | Chinese PLA General Hospital|Navy General Hospital, Beijing |
AML
|
April 2015 | Phase 2 |
| NCT02190695 | Fox Chase Cancer Center|M.D. Anderson Cancer Center|Teva Pharmaceuticals USA |
Acute Myeloid Leukemia|Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia
|
April 1, 2013 | Phase 2 |
| NCT04188405 | M.D. Anderson Cancer Center |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Myeloid Leukemia|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Acute Myeloid Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
|
May 17, 2020 | Phase 2 |
| NCT04051996 | Yale University|Pfizer |
ACUTE MYELOID LEUKEMIA
|
December 6, 2019 | Phase 2 |
| NCT04279379 | Beijing Tongren Hospital |
Extranodal NK+T-cell Lymphoma
|
April 1, 2020 | Phase 2 |
| NCT00861874 | University of Rochester |
Acute Myeloid Leukemia
|
January 2010 | Phase 1 |
| NCT03282825 | Dong Wha Pharmaceutical Co. Ltd. |
Advanced Breast Cancer
|
March 28, 2017 | Phase 1 |
| NCT03184935 | Sclnow Biotechnology Co., Ltd. |
Myelodysplastic Syndromes
|
December 2022 | Phase 1|Phase 2 |
| NCT03092674 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Myelodysplastic Syndrome|Myelodysplastic Syndrome With Excess Blasts-2
|
December 22, 2017 | Phase 2|Phase 3 |
| NCT03663751 | Shanghai Jiao Tong University School of Medicine |
Response Rate
|
July 1, 2018 | Phase 2 |
| NCT01026376 | Janssen-Cilag Farmaceutica Ltda.|Janssen Korea, Ltd., Korea |
Myelodysplastic Syndromes
|
June 2008 | |
| NCT04113616 | Kartos Therapeutics, Inc. |
Relapsed or Refractory Acute Myeloid Leukemia (AML)|Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)
|
September 25, 2019 | Phase 1|Phase 2 |
| NCT03381781 | Li Junmin|Ruijin Hospital |
Acute Myeloid Leukemia|P53 Mutation
|
March 2018 | Phase 2 |
| NCT00114257 | National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms
|
May 2005 | Phase 1 |
| NCT00882206 | Masonic Cancer Center, University of Minnesota |
Leukemia|Lymphoma
|
April 2009 | Phase 2 |
| NCT04713956 | Nanfang Hospital of Southern Medical University|Peking University People´s Hospital|Institute of Hematology and Blood Diseases Hospital|Guangzhou First People´s Hospital|Third Affiliated Hospital, Sun Yat-Sen University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|First People´s Hospital of Chenzhou|First Affiliated Hospital of Guangxi Medical University |
Myelodysplastic Syndrome|Allogeneic Hematopoietic Stem Cell Transplantation|Conditioning
|
January 15, 2021 | Phase 2|Phase 3 |
| NCT02257138 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Blasts More Than 20 Percent of Bone Marrow Nucleated Cells|Blasts More Than 20 Percent of Peripheral Blood White Cells|Myelodysplastic+Myeloproliferative Neoplasm|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
|
February 12, 2015 | Phase 1|Phase 2 |
| NCT04817241 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia
|
August 2, 2021 | Phase 1|Phase 2 |
| NCT04353479 | Shanghai Jiao Tong University School of Medicine |
Acute Myeloid Leukemia
|
April 25, 2020 | Phase 2 |
| NCT02121418 | University of Washington|National Cancer Institute (NCI) |
Chronic Myelomonocytic Leukemia-2|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Untreated Adult Acute Myeloid Leukemia
|
June 2014 | Not Applicable |
| NCT01846624 | David Iberri|Stanford University |
Acute Myeloid Leukemia (AML) With Multilineage Dysplasia Following Myelodysplastic Syndrome, in Adults|AML (Adult) With 11q23 (MLL) Abnormalities|AML (Adult) With Del (5q)|AML (Adult) With Inv (16) (p13; q22)|AML (Adult) With t (16;16) (p13; q22)|AML (Adult) With t (8; 21) (q22; q22)|Secondary AML (Adult)|Untreated AML (Adult)
|
June 2013 | Phase 2 |
| NCT02961101 | Han weidong|Chinese PLA General Hospital |
Malignancies Multiple
|
May 2016 | Phase 1|Phase 2 |
| NCT01834248 | Roswell Park Cancer Institute |
Acute Myeloid Leukemia|Alkylating Agent-Related Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndrome|Refractory Anemia With Excess Blasts in Transformation
|
July 30, 2013 | Phase 1 |
| NCT02204085 | Dana-Farber Cancer Institute |
Acute Myeloid Leukemia, in Relapse|Recurrent Adult Acute Myeloid Leukemia
|
September 2014 | Phase 1|Phase 2 |
| NCT05396859 | OHSU Knight Cancer Institute|Oregon Health and Science University|Genentech, Inc.|Taiho Oncology, Inc. |
Acute Myeloid Leukemia|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
|
October 28, 2022 | Phase 1 |
| NCT05348213 | Ruijin Hospital |
Diffuse Large B Cell Lymphoma
|
May 1, 2022 | Phase 2 |
| NCT05038592 | M.D. Anderson Cancer Center |
Chronic Myelomonocytic Leukemia|Chronic Myelomonocytic Leukemia-1|Chronic Myelomonocytic Leukemia-2|Myelodysplastic+Myeloproliferative Neoplasm
|
March 4, 2022 | Phase 1|Phase 2 |
| NCT01277484 | Seoul St. Mary´s Hospital|Janssen, LP |
Myelodysplastic Syndrome|Acute Myeloid Leukemia
|
January 2011 | Phase 1 |
| NCT02203773 | AbbVie|Genentech, Inc. |
Acute Myelogenous Leukemia|Myelogenous Leukemia|Treatment Naive AML
|
October 6, 2014 | Phase 1 |
| NCT00492401 | National Cancer Institute (NCI) |
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
May 2007 | Phase 2 |
| NCT03661307 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia|Recurrent Myelodysplastic Syndrome|Refractory Acute Myeloid Leukemia
|
October 31, 2018 | Phase 1|Phase 2 |
| NCT00075634 | National Cancer Institute (NCI) |
Recurrent Neuroblastoma|Unspecified Childhood Solid Tumor, Protocol Specific
|
December 2003 | Phase 1 |
| NCT02234037 | Emory University |
Leukemia
|
November 2013 | Phase 1 |
| NCT00748527 | Cancer Research UK|National Cancer Institute (NCI) |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer
|
July 2007 | Phase 2 |
| NCT01861314 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia
|
July 3, 2013 | Phase 1 |
| NCT01133886 | King´s College London|King´s College Hospital NHS Trust |
Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndrome
|
September 2010 | Phase 2 |
| NCT04553393 | Chinese PLA General Hospital |
Refractory or Relapsed Aggressive r+r B-NHL With Huge Tumor Burden
|
September 9, 2020 | Phase 1|Phase 2 |
| NCT02959164 | Varun Monga, MD|Holden Comprehensive Cancer Center|University of Iowa |
Pancreatic Ductal Adenocarcinoma|Sarcoma
|
December 2016 | Phase 1 |
| NCT00019825 | National Cancer Institute (NCI) |
Esophageal Cancer|Lung Cancer|Malignant Mesothelioma|Metastatic Cancer
|
October 1999 | Phase 1 |
| NCT03752138 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
|
March 31, 2019 | Phase 1 |
| NCT00042796 | National Cancer Institute (NCI) |
Childhood Acute Myeloblastic Leukemia With Maturation (M2)|Childhood Acute Promyelocytic Leukemia (M3)|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia
|
December 2002 | Phase 1 |
| NCT00661726 | HealthCore-NERI|National Heart, Lung, and Blood Institute (NHLBI) |
Thalassemia
|
January 2008 | Phase 2 |
| NCT01687400 | Washington University School of Medicine |
Leukemia, Myeloid, Acute|Myelodysplastic Syndromes
|
February 12, 2013 | Phase 2 |
| NCT04854889 | Institute of Hematology & Blood Diseases Hospital |
Refractory Aplastic Anemia
|
April 22, 2021 | Phase 2 |
| NCT02252107 | Radboud University Medical Center |
Acute Myeloid Leukemia (AML)
|
October 2014 | Phase 2 |
| NCT04945096 | The First Affiliated Hospital of Soochow University |
Engraft Failure|Relapse|GVHD
|
July 1, 2021 | Phase 3 |
| NCT03164057 | St. Jude Children´s Research Hospital |
Acute Myeloid Leukemia|Myelodysplastic Syndromes
|
June 15, 2017 | Phase 2 |
| NCT02951728 | Ruijin Hospital |
Diffuse Large B Cell Lymphoma
|
October 2016 | Phase 1|Phase 2 |
| NCT02487563 | The First Affiliated Hospital of Soochow University|Peking University People´s Hospital|Nanfang Hospital of Southern Medical University|Ruijin Hospital|Wuhan Union Hospital, China|Qilu Hospital of Shandong University|Children´s Hospital Of Soochow University|Fujian Medical University Union Hospital|Hebei Yanda Ludaopei Hospital |
Thrombocytopenia|Hematologic Diseases
|
October 2015 | Phase 3 |
| NCT02954653 | Pfizer |
Acute Myeloid Leukemia
|
November 28, 2016 | Phase 1 |
| NCT03445858 | Children´s Hospital Medical Center, Cincinnati |
Childhood Solid Tumor|Childhood Lymphoma|Relapsed Cancer|Refractory Cancer|Adult Solid Tumor|Adult Lymphoma
|
February 12, 2018 | Early Phase 1 |
| NCT05010772 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Myeloid Leukemia
|
October 25, 2021 | Phase 1 |
| NCT05586074 | Sunshine Lake Pharma Co., Ltd. |
Leukemia, Acute Myeloid (AML)
|
November 28, 2022 | Phase 3 |
| NCT02921061 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Mixed Phenotype Acute Leukemia|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Recurrent High Risk Myelodysplastic Syndrome|Refractory Acute Myeloid Leukemia|Refractory High Risk Myelodysplastic Syndrome|Untreated Adult Acute Myeloid Leukemia
|
November 17, 2016 | Phase 1|Phase 2 |
| NCT04340843 | National Cancer Institute (NCI) |
Locally Advanced Unresectable Primary Central Chondrosarcoma|Metastatic Primary Central Chondrosarcoma|Unresectable Primary Central Chondrosarcoma
|
July 6, 2020 | Phase 2 |
| NCT00260832 | Eisai Inc. |
Acute Myeloid Leukemia
|
November 2005 | Phase 3 |
| NCT05600894 | National Cancer Institute (NCI) |
Chronic Myelomonocytic Leukemia|Myelodysplastic Syndrome|Myelodysplastic Syndrome With Excess Blasts|Myeloproliferative Neoplasm
|
October 28, 2022 | Phase 2 |
| NCT02469415 | M.D. Anderson Cancer Center|CTI BioPharma |
Leukemia
|
September 30, 2015 | Phase 2 |
| NCT00778375 | M.D. Anderson Cancer Center|Eisai Inc.|Genzyme, a Sanofi Company |
Acute Myeloid Leukemia|Myelodysplastic Syndrome
|
October 2008 | Phase 2 |
| NCT00941109 | Eisai Inc. |
Myelodysplastic Syndrome
|
December 2009 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
In Vitro:
DMSO : ≥ 50 mg/mL ( 219.10 mM )
H 2 O : 20 mg/mL ( 87.64 mM ; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Preparing
Stock Solutions
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.3819 mL | 21.9096 mL | 43.8193 mL |
| 5 mM | 0.8764 mL | 4.3819 mL | 8.7639 mL |
| 10 mM | 0.4382 mL | 2.1910 mL | 4.3819 mL |
*
Please refer to the solubility information to select the appropriate solvent.
In Vivo:
-
1.
Add each solvent one by one: PBS
Solubility: 10 mg/mL (43.82 mM); Clear solution; Need ultrasonic
-
2.
-
3.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution
-
4.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution
*
All of the co-solvents are available by MCE.
References
- [1] Nakamura M, et al. Decitabine inhibits tumor cell proliferation and up-regulates E-cadherin expression in Epstein-Barr virus-associated gastric cancer. J Med Virol. 2016 Jul 19.
- [2] Parker WB. Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem Rev. 2009 Jul;109(7):2880-93.
- [3] Hagemann S, et al. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS One. 2011 Mar 7;6(3):e17388.
- [4] Requena CE, et al. The nucleotidohydrolases DCTPP1 and dUTPase are involved in the cellular response to decitabine. Biochem J. 2016 Jun 20.
- [5] Terse P, et al. Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice. Int J Toxicol. 2014 Mar-Apr;33(2):75-85.
- [6] Yu J, et al. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest. 2018 Jun 1;128(6):2376-2388.
- [7] Wang LX, et al. Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumorspecific cytotoxic T lymphocyte responses. PLoS One. 2013 May 9;8(5):e62924.
Synonyms
1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-
s-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-
4-Amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one
5-Aza-2′-deoxycytidine
5-Azadeoxycytidine
2-Desoxy-5-azacytidine
2′-Deoxy-5-azacytidine
Decitabine
NSC 127716
DAC
Dacogen
β-Decitabine
5-Aza-2-deoxycytidine
4-Amino-1-(2-deoxy-β-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one
A 2232
NSC127716
Request a Quote
Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.
Information
Customer service
My account
Powered by Arctom
Copyright © 2021 Arctom. All rights reserved.